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Abstract
Background: The aim of this study was to evaluate HE4, CA125 and ROMA in the preoperative differentiation
benign ovarian diseases from epithelial ovarian cancer depending on the menopausal status.
Methods: In order to estimate markers’ concentrations in the serum of women with benign ovarian disease (n = 128)
and with epithelial ovarian carcinoma (n = 96) the electrochemiluminescence (ECLIA) technique has been applied.
Results: Using the ROC analysis, although no statistical differences were found among their AUCs, the ROMA
algorithm seems to be effective in gathering the diverse performance of HE4 and CA125. The AUC for HE4, CA125 and
ROMA for all patients were: 0.895; 0.879 and 0.918, respectively. At established new optimal cutoff values for HE4,
CA125 and ROMA we found higher specificity in postmenopausal compared to premenopausal women (96.9 vs 89.8 %
and 97.7 vs 84.1 % and 95.9 vs 89.1 %, respectively). The sensitivity of HE4 in pre- and postmenopausal women was
similar (83.5 vs 83.8 %), while for CA125 was the highest in premenopausal women (87.0 vs 84.1 %). For HE4, CA125
and ROMA the negative predictive value was high (97.6, 93.9 and 94.4 %, respectively).
Conclusions: The ROMA algorithm shows the best diagnostic performance to distinguish epithelial ovarian cancer
from benign ovarian disease. We found the high specificity of HE4 and CA125 while differentiating ovarian benign
diseases from epithelial ovarian cancer in postmenopausal women and the high sensitivity of CA125 in detecting
epithelial ovarian cancer in premenopausal patients.
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Background
Ovarian cancer is the most lethal cancer among gynae-
cological malignancies. In 2012, it was estimated that
238,719 cases were diagnosed and 151,905 women died
from this disease worldwide [1]. The estimated number
of new ovarian cancer cases in Europe in 2012 was
65,538 with 42,704 deaths [2]. In Poland, ovarian cancer
is the second most frequent invasive malignancy of the
female genital tract after cancers of the uterine corpus,
with an estimated 3,600 cases diagnosed annually. Ap-
proximately 2,600 women die each year from ovarian
cancer, representing the most common cause of death
among women with gynaecological malignancies [3].
Taking into consideration the late stage of diagnosis,
our inability to diagnose ovarian cancer at an early stage
remains the major problem. Despite the acceptance re-
garding the influence of reproductive hormones on ovar-
ian cancer risk and considerable advances in the
understanding of epithelial ovarian carcinogenesis on a
molecular level, there is no complete understanding of
the biologic processes underlying malignant transform-
ation of ovarian surface epithelium [4–6]. The contem-
porary diagnostic standard of ovarian cancer includes
transvaginal ultrasound and serum measurement of
CA125. However this method has insufficient specificity,
especially in women before menopause. A wide range of
diagnostic approaches e.g. panels of biomarkers,
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algorithms, ultrasound and other imaging methods are
being investigated at present [7, 8]. Among them the
usefulness of HE4 in the diagnosis of ovarian cancer has
been researched by a few groups [9–13].
Both CA125 and HE4 with menopausal status are
currently being incorporated into the Risk of Ovarian
Malignancy Algorithm (ROMA) in order to discern ma-
lignant from benign pelvic masses. Many studies have
demonstrated the clinical utility of serum HE4 and
ROMA in women with a complex pelvic mass and may
provide even greater accuracy in the risk stratification
of epithelial ovarian carcinoma [10, 11, 13, 14].
This study aimed to evaluate HE4, CA125 and ROMA
in the preoperative differentiation benign ovarian dis-
eases from epithelial ovarian cancer depending on the
menopausal status.
Methods
The analysis of the preoperative serum concentrations of
CA125, HE4 and the ROMA values was performed on
the material obtained from the Caucasian women surgi-
cally treated from 2012 to 2016 at the Department of
Gynaecologic Oncology of the Maria Sklodowska-
Curie Memorial Bialystok Oncology Centre and at the
Department of Gynaecology and Obstetrics of the
Jedrzej Sniadecki Memorial Hospital in Bialystok
(Poland). It was done on account of benign ovarian
disease (n = 128) and epithelial ovarian cancer (n = 96)
according to the international treatment guidelines for
ovarian cancer patients, including primary cytoreduc-
tive surgery followed by platinum-containing chemo-
therapy [15].
All surgical specimens were reviewed by 2 dedicated
gynaecologic pathologists. Tumours were classified accord-
ing to the WHO histological criteria [16] and divided into
subtypes: serous 59 (61.5 %), mucinous 10 (10.4 %), endo-
metrioid 13 (13.5 %), clear cell 5 (5.2 %), others (mixed
non-differentiated) 8 (8.3 %) and no data 1 (1.1 %). The
samples were grouped by the following histological grades:
5 (5.2 %) were classified as low-grade (G1), 10 (10.4 %) were
medium-grade (G2) and 78 (81.3 %) were in high-grade
(G3). Most of the epithelial ovarian cancers were of high
grade and were diagnosed at an advanced stage. A total of
24 (25 %) were diagnosed with stage I disease, 11 (11.5 %)
with stage II, 48 (50 %) with stage III and 12 (12.5 %) with
stage IV disease, according to the Fédération Internationale
de Gynécologie et d'Obstétrique (FIGO) classification cri-
teria [17]. The benign disease group with serous, mucinous,
endometriosis, mixed and other cysts of the ovary was also
examined histologically. The women were made familiar
with procedures and gave their written consent before the
study enrolment. The study was approved by the Bioethics
Committee of the Medical University of Bialystok (protocol
No. R-I-002/68/2012).
Blood samples were collected to Vacutainer sterile
tubes (Becton Dickinson, USA) to clot. Samples were
then centrifuged for 10 min at 3000 rpm. Recovered sera
were pipetted into sterile tubes (Nunc, Denmark) and
stored at −80 °C. Concentrations of HE4 and CA125 were
assessed with the electrochemiluminescence (ECLIA) tech-
nique on Cobas e411 (Roche Diagnostics, Switzerland)
analyser, based on standard protocols. Cutoff levels were 35
U/mL for CA125 and 140 pmol/L for HE4. The range of
HE4 and CA125 assays were 15–1500 pmol/l and 0.600–
5000 U/ml, respectively. The test precision for both
markers was performed in accordance with the protocol
guidelines of Clinical and Laboratory Standards Institute
(CLSI) [18]. All test runs were duplicated. According to the
indications of the manufacturer, an index of ROMA ≥11.4
and ≥29.9 % indicates a high risk for the presence of epithe-
lial ovarian cancer in pre- and postmenopausal women, re-
spectively. The patients’ clinical status was not known by
the people carrying out the assays, and the results of these
assays were disclosed to the surgeons only after the pa-
tients’ disease status was recorded.
Statistical analysis
ROMA classifies patients as being at a low or at a high
risk for malignant disease using the following
algorithms:
Before menopause: PI = ‐ 12.0 + 2.38 × LN [HE4] +
0.0626 × LN [CA125]
After menopause: PI = ‐ 8.09 + 1.04 × LN [HE4] +
0.732 × LN [CA125]
ROMA value (%) = ePI/[1 + ePI] x 100%
PI - predictive index, LN - natural logarithm, e - base
of natural logarithm
The HE4, CA125 and ROMA median values were
compared with the Mann-Whitney U test, and the
Kruskal-Wallis one-way analysis of variance by ranks
(ANOVA) and the Spearman’s rank correlation coeffi-
cient (rho). Categorical variables were compared with
the Pearson’s chi-square test with Yates correction and
Fisher’s exact test based on the Statistica software pack-
age 10.0 PL (StatSoft, Inc. StatSoft Poland Ltd.). Re-
ceiver operator characteristic (ROC) curves were
constructed, and the area under the curve (ROC-AUC)
with a 95 % confidence interval (95%CI) was calculated.
Sensitivity and specificity were calculated in pre- and
postmenopausal women separately and independently
of menopausal status. In order to identify patients with
cancer, the best cutoff point of CA125, HE4 and ROMA
with regard to best values of sensitivity, specificity,
positive (PPV) and negative predictive values (NPV)
were evaluated. For all statistical comparisons, a p-
value of <0.05 was considered statistically significant.
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Results
Of the 224 evaluable women, 120 were premenopausal
(age: median: 36, range: 25–49) and 104 postmenopausal
(age: median: 63, range 53–74 years). The clinical charac-
teristics information of individuals enrolled in our study
were shown in Table 1. High serum levels of HE4, CA125
and values of ROMA were found in patients with epithe-
lial ovarian cancer rather than in those with benign dis-
eases (p < 0.001). The total median value of HE4, CA125
and ROMA in pre- and postmenopausal women with epi-
thelial ovarian cancer was statistically higher than that in
the women with benign diseases (p < 0.001). HE4, CA125
and ROMA values determined in pre- and postmeno-
pausal women with benign diseases and with epithelial
ovarian cancer are shown in Table 2.
In the present study we established new cutoff values spe-
cific to the examined population for each biomarker, and
verified them using ROC analysis to calculate the optimal
cutoffs. The best cutoff points distinguishing malignant vs.
benign disease for HE4, CA125 and ROMA were 72.3
pmol/l; 62.2 U/ml and 20.1 %, respectively. Before and after
the menopause these values were as follows: 70.3 vs 109.1
pmol/l for HE4; 64.6 vs 39.4 U/ml for CA125 and 14.9 vs
33.4 % for ROMA. The level of optimal cutoff values for
HE4 was lower (72.3 pmol/l) than the recommended one
(140 pmol/l), whereas for CA125 it was higher (62.2 U/ml)
than the suggested one (35 U/ml), for all patients. The diag-
nosis accuracy of HE4, CA125 and ROMA was assessed by
estimating ROC and AUC for all patients with ovarian can-
cer versus benign diseases. The AUC values for HE4,
CA125 and ROMA were 0.895 (confidence interval (CI)
95 %, 0.838–0.951), 0.879 (CI 95 %, 0.818–0.941) and 0.918
(CI 95 %, 0.853–0.938), respectively. The highest ROC-
AUC was for ROMA, followed by HE4. When alternative
thresholds of 72.3 pmol/l (all), 70.3 pmol/l (premenopausal)
and 109.1 pmol/l (postmenopausal) for HE4 were used, the
sensitivities of HE4 in detecting epithelial ovarian cancer
were enhanced, by 84.1 % (all), 83.5 % (pre-) and 83.8 %
(post-), with just a slight loss of specificities from 97.5 to
86.3 % (all) and 98.6 to 89.8 % (pre-), respectively. In post-
menopausal women specificity of HE4 rose from 94.2 to
96.9 %. The PPV for HE4 was 45.2 %, 46.2 and 86.8, re-
spectively. The NPV was 97.6, 96.7 and 89.6 %, respectively.
While in the case of CA125, the sensitivities obtained by
using a modified cutoff value were significantly lower than
when using the preferred one in postmenopausal group.
The specificities were elevated to 82.4 % (all), 84.1 % (pre-)
and 97.7 % (post-). The PPV for CA125 was 41.6, 44.8 and
91.7 % and the NPV was 93.9, 94.8 and 92.8 %, respectively.
In the analysed groups no clear differences were found for
ROMA values between optimal and preferred value settings
(Table 3, Fig. 1).
Discussion
The use of serum markers in a ovarian carcinoma risk clas-
sifier is novel but is strongly supported by literature [19].
Since HE4 is overexpressed in ovarian cancers relative to
normal tissues, Hellstrom et al. [20] examined the potential
of HE4 as a secreted biomarker for ovarian cancer. Studies
performed by Bon et al. [21] showed the possibility of using
HE4 in ovarian cancer diagnostics. The HE4 serum levels
in healthy women have been reported to range from 60
pmol/l to 150 pmol/l. The reasons for this wide range
might be due to the relationship between increasing HE4
serum levels and increasing age. Women older than 49 years
of age have higher concentrations in comparison with
Table 1 Clinicopathological characteristics of the patients
Pathology All patients n (%) Menopausal status
Pre- n (%) Post- n (%)
Benign ovarian diseases 128 87 41
Histologic type
Serous 46 (35.9) 25 (28.7) 21 (51.2)
Mucinous 13 (10.2) 7 (8.1) 6 (14.6)
Endometriosis 33 (25.8) 31 (35.6) 2 (4.9)
Mixed 12 (9.4) 8 (9.2) 4 (9.8)
Other 24 (18.7) 16 (18.4) 8 (19.5)
Epithelial ovarian cancer 96 33 63
Histologic type
Serous 59 (61.5) 17 (51.4) 42 (66.7)
Endometrioid 13 (13.5) 5 (15.2) 8 (12.7)
Mucinous 10 (10.4) 6 (18.2) 4 (6.3)
Clear cell 5 (5.2) 3 (9.1) 2 (3.2)
Mixed/Undifferentiated 8 (8.3) 2 (6.1) 6 (9.5)
No data 1 (1.1) 0 (0) 1 (1.6)
FIGO stage
IA 5 (5.2) 3 (9.1) 2 (3.2)
IB 4 (4.1) 2 (6.1) 2 (3.2)
IC 15 (15.6) 8 (24.3) 7 (11.1)
IIA 2 (2.1) 0 (0) 2 (3.2)
IIB 1 (1.1) 1 (3.0) 0 (0)
IIC 8 (8.3) 3 (9.1) 5 (7.9)
IIIA 3 (3.1) 1 (3.0) 2 (3.2)
IIIB 9 (9.4) 1 (3.0) 8 (12.7)
IIIC 36 (37.5) 11 (33.3) 25 (39.6)
IV 12 (12.5) 2 (6.1) 10 (15.9)
not staged 1 (1.1) 1 (3.0) 0 (0)
Grade
G1 5 (5.2) 3 (9.1) 2 (3.2)
G2 10 (10.4) 6 (18.2) 4 (6.3)
G3 78 (81.3) 23 (69.7) 55 (87.3)
unknown 3 (3.1) 1 (3.0) 2 (3.2)
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women younger than 40 years. There is a correlation be-
tween the histological type and the serum concentration of
HE4 with higher concentrations in serous ovarian cancer
and with concentrations being lowest in patients with mu-
cinous ovarian carcinomas [22–24].
Postmenopausal women with CA125 concentrations
greater than 35 kU/L should be taken into consideration
for transvaginal ultrasound examination as well as a
computed tomography scan. The CA125 concentrations
greater than 95 kU/L were reported to discriminate ma-
lignant from non-malignant pelvic masses with a posi-
tive predictive value of 95 % [25]. For premenopausal
women, the American College of Obstetrics and Gyne-
cologists suggested that patients with a pelvic mass and
CA125 concentrations greater than 200 kU/L should be
referred to a gynaecologist for consultation [19, 26].
In our recent study we showed that in the early stage of
endometrioid endometrial cancer, HE4 can serve as a pre-
operative tool that can help to identify postmenopausal
women who may require lymphadenectomy [27]. The
present study aimed at evaluating and comparing the role
of HE4, CA125 and ROMA value for the differential diag-
nosis of epithelial ovarian cancer. A cohort of women with
benign ovarian diseases was used as the control group.
We found that serum concentrations of HE4, CA125 and
the ROMA values were significantly elevated in women
with epithelial ovarian cancer compared to women with
benign disease, both before and after the menopause, be-
ing similar to the results from other studies [28]. The data
obtained from our study suggests that ROMA algorithm
appears to have the best diagnostic performance in distin-
guishing epithelial ovarian cancer from benign ovarian
diseases. Actually, using the ROC analysis while no statis-
tical differences were found among their AUCs, the
ROMA algorithm turns out to be effective in recognising
the diverse performance of HE4 and CA125. The AUC for
HE4, CA125 and ROMA for all patients were: 0.895;
0.879 and 0.918, respectively. Our results fit the range ob-
tained by other authors: 0.85–0.96; 0.81–0.95 and 0.88–
0.97 [20, 22, 29]. It is worth realising that the ROC
Table 2 The serum levels of HE4 and CA125 and ROMA values in the examined groups
Benign ovarian diseases Epithelial ovarian cancer p-value
Median (range) Median (range)
all patients
HE4 (pmol/l) 53.4 (22.1–328.6) 118.4 (37.4–1921.4) <0.001
CA125 (U/ml) 19.4 (4.2–150.3) 116.3 (14.4–3798.4) <0.001
ROMA (%) 12.4 (0.8–42.6) 50.4 (21.8–99.1) <0.001
premenopausal
HE4 (pmol/l) 50.4 (22.1–98.4) 84.1 (37.4–762.4) <0.001
CA125 (U/ml) 23.3 (4.2–150.3) 75.4 (14.4–706.2) <0.001
ROMA (%) 10.2 (0.8–35.8) 28.6 (21.8–85.6) <0.001
postmenopausal
HE4 (pmol/l) 56.4 (32.8–328.6) 147.8 (54.9–1921.4) <0.001
CA125 (U/ml) 12.3 (9.4–113.3) 168.7 (15.9–3798.4) <0.001
ROMA (%) 14.6 (1.2–42.6) 72.2 (30.2–99.1) <0.001
Table 3 Diagnostic accuracy for discriminating between benign ovarian diseases and epithelial ovarian cancer
BOD vs
EOC
Marker ROC-AUC (95 % CI) Cutoff optimal/
preferred
Sensitivity (%)
optimal/preferred
Specificity (%)
optimal/preferred
PPV (%)
optimal/preferred
NPV (%)
optimal/preferred
all HE4 0.895 (0.838–0.951) 72.3 / 140 (pmol/l) 84.1 / 67.1 86.3 / 97.5 45.2 / 87.4 97.6 / 92.1
CA125 0.879 (0.818–0.941) 62.2 / 35 (U/ml) 83.1 / 81.9 82.4 / 74.1 41.6 / 36.9 93.9 / 96.2
ROMA 0.918 (0.853–0.938) 20.1 / 11.4; 29.9 (%) 86.2 / 84.8 86.8 / 88.2 39.4 / 36.3 94.4 / 96.6
pre-
menopausal
HE4 0.845 (0.806–0.894) 70.3 / 140 (pmol/l) 83.5 / 68.2 89.8 / 98.6 46.2 / 86.4 96.7 / 94.4
CA125 0.833 (0.753–0.944) 64.6 / 35 (U/ml) 87.0 / 86.6 84.1 / 70.9 44.8 / 33.6 94.8 / 96.1
ROMA 0.854 (0.778–0.876) 14.9 / 11.4 (%) 86.8 / 86.2 89.1 / 88.8 42.1 / 39.6 97.2 / 98.7
post-
menopausal
HE4 0.916 (0.841–0.979) 109.1 / 140 (pmol/l) 83.8 / 87.1 96.9 / 94.2 86.8 / 92.8 89.6 / 86.2
CA125 0.904 (0.855–0.943) 39.4 / 35 (U/ml) 84.1 / 91.9 96.7 / 89.8 91.7 / 83.2 92.8 / 94.4
ROMA 0.931 (0.898–0.959) 33.4 / 29.9 (%) 89.0 / 86.8 95.9 / 92.2 91.9 / 89.4 94.2 / 94.9
BOD benign ovarian diseases, EOC epithelial ovarian cancer
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analysis identifies optimal cutoffs which are different from
the recommended routinely used ones for HE4 and
CA125, insinuating the possibility of adjusting the cutoff
points to the clinical requirements of a given diagnostic
setting, as it was formerly reported [30–32]. Therefore, we
decided not to use the limits specified by the assay proce-
dures. The values were determined on the basis of the
highest accuracy (minimal false negative and false positive
results) and cutoffs were calculated depending on the
menopausal status. Both in pre- and postmenopausal
women, HE4, CA125 and ROMA values acquired similar
sensitivity. However, in postmenopausal women all tested
markers were characterized by higher specificity. For HE4,
CA125 and ROMA the negative predictive value was high.
When using the recommended cutoff points indicated by
the manufacturers, HE4 yields the best specificity perfor-
mances in both pre- and postmenopausal patients while
CA125 displays the best sensitivity.
Van Gorp et al. [33], supplied insufficient sensitivity of
HE4. The cutoff value of HE4 (150 pmol/l) in this study
was based on the manufacturer’s protocol. HE4 cutoff
point of 70 pmol/l used by Moore et al. [34], achieved
74.5 % of sensitivity and 83.3 % of specificity. Our study
showed that the best cutoff point for HE4 was 72.3
pmol/l and depicted 84.1 % of sensitivity and 86.3 % of
specificity. The best cutoff values for ROMA in pre- and
postmenopausal women, set in the present study, were
slightly higher from those suggested by other authors
[35, 36]. Moore et al. [34] found higher sensitivity and
specificity of ROMA in premenopausal compared to
postmenopausal women (92.3 and 75.0 % vs 76.5 and
74.8 %, respectively). The cutoff values for ROMA were:
13.1 and 27.7 %, respectively. ROMA calculation enabled
93.8 % of ovarian cancer cases to be correctly classified
as a high-risk group. For cutoff values suggested by
Moore et al. [34] and Bandiera et al. [37] demonstrated
84.6 % of sensitivity and 81.2 % of specificity. Similar re-
sults were outlined in a multicentre prospective study
from six countries in Asia [38]. In our study, at estab-
lished new optimal cutoff values for ROMA, we found
higher sensitivity and specificity in postmenopausal
compared to premenopausal women (89.0 and 95.9 % vs
86.8 and 89.1 %, respectively). ROMA also showed sig-
nificant difference in comparison with HE4 and CA125
for discriminating benign ovarian diseases and epithelial
ovarian cancer in all the patients and postmenopausal
Fig. 1 The ROC curves of HE4, CA125 and ROMA in all patients (a), premenopausal (b) and postmenopausal (c). Area under the ROC curve of
HE4, CA125 and ROMA (a): 0.895 vs 0.879 vs 0.918, (b): 0.845 vs 0.833 vs 0.854 and (c): 0.916 vs 0.904 vs 0.931, respectively
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women. The differences between values of sensitivity
and specificity probably emerge from variations between
the studied groups (different types of epithelial ovarian
cancers and the number of investigated cases). Further-
more, our cutoff values were not set at 75 % level of spe-
cificity, but we estimated them based on the ROC curve
points. Thus, these results need to be confirmed by
more well-designed research studies.
Conclusions
In conclusion, this study confirms the diagnostic role of
HE4 and ROMA in epithelial ovarian cancer. The ROMA
algorithm appears to show the best diagnostic perform-
ance to differentiate epithelial ovarian cancer from benign
ovarian disease. We found the high specificity of HE4 and
CA125 while discriminating ovarian benign diseases from
epithelial ovarian cancer in postmenopausal women and
the high sensitivity of CA125 in detecting epithelial ovar-
ian cancer in premenopausal patients. Concisely, our
study shows that ROMA algorithm more accurately se-
lects patients with a high risk of ovarian epithelial cancer
which enables to direct them to centres specializing in
oncological gynaecology.
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